Aurora Cannabis General and Administrative Expenses 2011-2026 | ACB

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Aurora Cannabis

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	119 M	265 M	279 M	80.4 M	14.4 M	3.93 M	2.61 M	281 K	153 K	250 K	182 K

All numbers in CAD currency

Indicator range from annual reports

Maximum	Minimum	Average
279 M	153 K	69.7 M

General and Administrative Expenses of other stocks in the Drug manufacturers industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Alimera Sciences ALIM	18.5 M	-	-	$ 142 M	USA
Adamis Pharmaceuticals Corporation ADMP	13.2 M	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	138 M	-	-	$ 754 M	USA
AcelRx Pharmaceuticals ACRX	8.53 M	-	7.5 %	$ 6.35 M	USA
Canopy Growth Corporation CGC	170 M	$ 1.02	-	$ 110 M	Canada
Agile Therapeutics AGRX	10.5 M	-	10.11 %	$ 58.2 M	USA
Cronos Group CRON	95.9 M	$ 2.54	1.6 %	$ 1.33 B	Canada
Assertio Holdings ASRT	69 M	$ 11.77	1.99 %	$ 836 M	USA
DURECT Corporation DRRX	14.4 M	-	-	$ 50.1 M	USA
Avadel Pharmaceuticals plc AVDL	181 M	-	-	$ 2.06 B	France
Eagle Pharmaceuticals EGRX	107 M	-	-39.89 %	$ 27.7 M	USA
Evolus EOLS	221 M	$ 5.04	0.6 %	$ 325 M	USA
Evoke Pharma EVOK	12.2 M	-	-	$ 36.6 M	USA
Calliditas Therapeutics AB (publ) CALT	390 M	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	58.2 M	-	2.45 %	$ 38.1 M	Canada
Catalent CTLT	935 M	-	-	$ 11.5 B	USA
Cumberland Pharmaceuticals CPIX	11.1 M	$ 3.06	0.66 %	$ 43 M	USA
Jupiter Wellness JUPW	39.6 M	-	-	$ 33.6 M	USA
Athenex ATNX	44.9 M	-	-23.39 %	$ 1.76 M	USA
Endo International plc ENDP	568 M	-	-	$ 28.9 M	Irlanda
Harrow Health HROW	153 M	$ 34.91	2.38 %	$ 1.28 B	USA
Emergent BioSolutions EBS	368 M	$ 8.33	3.22 %	$ 426 M	USA
OrganiGram Holdings OGI	12.8 M	$ 1.42	0.71 %	$ 402 M	Canada
China Pharma Holdings CPHI	1.78 M	$ 0.62	2.94 %	$ 10.8 M	China
Sundial Growers SNDL	38.4 M	$ 1.44	-4.64 %	$ 3.37 M	Canada
Organogenesis Holdings ORGO	295 M	$ 2.58	-2.27 %	$ 340 M	USA
Pacira BioSciences PCRX	294 M	$ 22.69	-2.45 %	$ 1.05 B	USA
ProPhase Labs PRPH	34.4 M	-	-	$ 5.07 M	USA
Lannett Company LCI	81 M	-	1.15 %	$ 7.11 M	USA
Radius Health RDUS	131 M	-	-	$ 1.42 B	USA
Perrigo Company plc PRGO	436 M	$ 9.72	4.4 %	$ 1.35 B	USA
Neoleukin Therapeutics NLTX	11.2 M	-	-	$ 193 M	Canada
Sonoma Pharmaceuticals SNOA	7.36 M	$ 2.4	-2.24 %	$ 2.98 M	USA
Relmada Therapeutics RLMD	48.9 M	$ 6.18	4.57 %	$ 186 M	USA
Rockwell Medical RMTI	12.1 M	$ 0.96	6.61 %	$ 22.4 M	USA
PetIQ PETQ	196 M	-	1.64 %	$ 400 M	USA
OptiNose OPTN	79.8 M	-	-	$ 1.08 B	USA
PLx Pharma PLXP	40 M	-	-27.8 %	$ 2.56 M	USA
SCYNEXIS SCYX	14.4 M	$ 0.9	4.68 %	$ 44.9 M	USA
Recro Pharma REPH	21 M	-	-4.76 %	$ 65.3 M	USA
TherapeuticsMD TXMD	8.9 M	$ 2.17	-	$ 22.7 M	USA
Solid Biosciences SLDB	33.3 M	$ 7.48	2.33 %	$ 305 M	USA
Veru VERU	31.2 M	$ 2.37	-0.84 %	$ 320 M	USA
Tilray TLRY	165 M	$ 6.9	0.15 %	$ 4.26 B	Canada
Viatris VTRS	4.07 B	$ 13.51	-	$ 16.2 B	USA
Tricida TCDA	37.6 M	-	-	$ 3.25 M	USA
Zynerba Pharmaceuticals ZYNE	14.2 M	-	-	$ 55.5 M	USA
Zomedica Corp. ZOM	24.5 M	-	-0.21 %	$ 98 M	USA